MedDataX Logo

A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia

NCT ID: NCT02255435

Last Updated: 2025-12-31

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

172 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, researchers are learning more about RTA 408, also known as omaveloxolone, BIIB141, or SKYCLARYS®. The main goal of this study is to learn more about the safety of RTA 408 and how it affects physical effort, movement, coordination, and how participants feel in daily life.

The main questions researchers want to answer in this study are:

* How much physical effort can a participant produce during a cycling test after 12 weeks of treatment?
* How do scores on the modified Friedreich's Ataxia Rating Scale (mFARS) change after 48 weeks?

Researchers will use the modified Friedreich's Ataxia Rating Scale (mFARS) to measure how FA affects the nervous system. The mFARS looks at movement ability, balance, coordination, speech, and how well the arms and legs work.

They will also use a cycling test to measure physical effort, along with questionnaires to learn how participants feel and function in daily life.

Safety will also be tested using physical exams, vital sign checks, echocardiograms (ECHO), electrocardiograms (ECG), and blood and urine tests.

The study will be done in 2 main parts, followed by an optional Extension period:

* In Part 1, participants will be randomly assigned to take different doses of RTA 408 or a placebo by mouth once a day for 12 weeks. A placebo looks like the study drug but contains no real medicine.
* Researchers will compare these doses to decide which one to use in Part 2.
* In Part 2, a different group of participants will take either the chosen dose of RTA 408 (150 mg) or placebo once a day for 48 weeks.
* Participants who complete Part 1 or Part 2 may be able to join an Extension period, where everyone receives RTA 408.
* In the Extension period, participants will continue to receive RTA 408 until the drug becomes commercially available or until they leave the study
* Participants in Part 1 will have up to 9 study visits and 2 phone calls. If they do not move onto the Extension period, they will stay in the study for up to 20 weeks.
* Participants in Part 2 will have up to 10 study visits and 3 phone calls. If they do not move onto the Extension period, they will stay in the study for up to 61 weeks.
* Participants in the Extension period will have 2 visits in the first month, followed by visits every 6 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Friedreich's ataxia is an autosomal recessive cerebellar ataxia caused by triplet-repeat expansions. The causative mutation is a trinucleotide (GAA) repeat expansion in the first intron of the frataxin gene, leading to impaired transcription of frataxin. The pathological consequences of frataxin deficiency include a severe disruption of iron-sulfur cluster biosynthesis, mitochondrial iron overload coupled to cellular iron dysregulation, and an increased sensitivity to oxidative stress.

A hallmark of Friedreich's ataxia is impairment of antioxidative defense mechanisms, which play a major role in disease progression. Studies have demonstrated that nuclear factor erythroid-derived 2-related factor 2 (Nrf2) signaling is grossly impaired in participants with Friedreich's ataxia. Therefore, the ability of omaveloxolone (RTA 408) to activate Nrf2 and induce antioxidant target genes is hypothesized to be therapeutic in participants with Friedreich's ataxia.

This 2-part study will evaluate the efficacy, safety, and pharmacodynamics of omaveloxolone (RTA 408) in the treatment of participants with Friedreich's ataxia.

Part 1: The first part of this study will be a randomized, placebo-controlled, double-blind, dose-escalation study to evaluate the safety of omaveloxolone (RTA 408) at various doses in participants with Friedreich's ataxia.

Part 2: The second part of this study is a randomized, placebo-controlled, double-blind, parallel-group study to evaluate the safety and efficacy of omaveloxolone (RTA 408) 150 mg in participants with Friedreich's ataxia. Participants enrolled in Part 2 will be randomized 1:1 to receive omaveloxolone (RTA 408) 150 mg or placebo.

Extension: The extension will assess long-term safety and tolerability of omaveloxolone (RTA 408) in qualified participants with Friedreich's ataxia following completion of Part 1 or Part 2. Participants will not be unblinded to study treatment in Part 1 or Part 2 upon entering the extension study. Participants will receive open-label omaveloxolone (RTA 408) at 150 mg once daily.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Friedreich Ataxia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

RTA 408 RTA 408 Capsules Oxidative Stress Mitochondrial dysfunction omaveloxolone

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part 1 Omaveloxolone Capsules 2.5 and 5 mg

omaveloxolone (RTA 408) Capsules, 2.5 mg administered orally one daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks

Group Type EXPERIMENTAL

Omaveloxolone Capsules, 2.5 mg

Intervention Type DRUG

Omaveloxolone Capsules, 5 mg

Intervention Type DRUG

Part 1 Omaveloxolone Capsules 10 mg

omaveloxolone (RTA 408) Capsules, 10 mg administered orally once daily for 12 weeks

Group Type EXPERIMENTAL

Omaveloxolone Capsules, 10 mg

Intervention Type DRUG

Part 1 Omaveloxolone Capsules 20 mg

Omaveloxolone (RTA 408) Capsules, 20 mg administered orally once daily for 12 weeks

Group Type EXPERIMENTAL

Omaveloxolone Capsules, 20 mg

Intervention Type DRUG

Part 1 Omaveloxolone Capsules 40 mg

Omaveloxolone (RTA 408) Capsules, 40 mg administered orally once daily for 12 weeks

Group Type EXPERIMENTAL

Omaveloxolone Capsules, 40 mg

Intervention Type DRUG

Part 1 Omaveloxolone Capsules 80 mg

Omaveloxolone (RTA 408) Capsules, 80 mg administered orally once daily for 12 weeks

Group Type EXPERIMENTAL

Omaveloxolone Capsules, 80 mg

Intervention Type DRUG

Part 1 Omaveloxolone Capsules 160 mg

Omaveloxolone (RTA 408) Capsules, 160 mg administered orally once daily for 12 weeks

Group Type EXPERIMENTAL

Omaveloxolone Capsules, 160 mg

Intervention Type DRUG

Part 1 Omaveloxolone Capsules 300 mg

Omaveloxolone (RTA 408) Capsules, 300 mg administered orally once daily for 12 weeks

Group Type EXPERIMENTAL

Omaveloxolone Capsules, 300 mg

Intervention Type DRUG

Part 1 Placebo Capsules

Placebo capsules administered orally once daily for 12 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Part 2 Placebo Capsules

Placebo capsules administered orally once daily for 48 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Part 2 Omaveloxolone Capsules 150 mg

Omaveloxolone (RTA 408) Capsules, 150 mg administered orally once daily for 48 weeks

Group Type EXPERIMENTAL

Omaveloxolone Capsules, 150 mg

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Omaveloxolone Capsules, 2.5 mg

Intervention Type DRUG

Omaveloxolone Capsules, 5 mg

Intervention Type DRUG

Omaveloxolone Capsules, 10 mg

Intervention Type DRUG

Placebo

Intervention Type DRUG

Omaveloxolone Capsules, 20 mg

Intervention Type DRUG

Omaveloxolone Capsules, 40 mg

Intervention Type DRUG

Omaveloxolone Capsules, 80 mg

Intervention Type DRUG

Omaveloxolone Capsules, 160 mg

Intervention Type DRUG

Omaveloxolone Capsules, 300 mg

Intervention Type DRUG

Omaveloxolone Capsules, 150 mg

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RTA 408 Capsules 2.5 mg RTA 408 capsules, 5 mg RTA 408 capsules, 10 mg RTA 408 capsules, 20 mg RTA 408 capsules, 40 mg RTA 408 capsules, 80 mg RTA 408 capsules, 160 mg RTA 408 capsules, 300 mg RTA 408 capsules, 150 mg

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Have genetically confirmed Friedreich's ataxia
2. Have a modified FARS score ≥20 and ≤80
3. Be male or female and ≥16 years of age and ≤40 years of age
4. Have no changes to exercise regimen within 30 days prior to Study Day 1 and be willing to remain on the same exercise regimen during the 16-week study period
5. Have the ability to complete maximal exercise testing
6. Be able to swallow capsules

Exclusion Criteria

1. Have uncontrolled diabetes (HbA1c \>11.0%)
2. Have B-type natriuretic peptide value \>200 pg/mL
3. Have a history of clinically significant left-sided heart disease and/or clinically significant cardiac disease
4. Have known active fungal, bacterial, and/or viral infection, including human immunodeficiency virus or hepatitis virus (B or C)
5. Have known or suspected active drug or alcohol abuse
6. Have clinically significant abnormalities of clinical hematology or biochemistry, including but not limited to elevations greater than 1.5 times the upper limit of normal of aspartate aminotransferase, or alanine aminotransferase
7. Have any abnormal laboratory test value or serious pre-existing medical condition that, in the opinion of the investigator, would put the patient at risk by study enrollment
8. Have taken any of the following drugs within 7 days prior to Study Day 1 or plan to take any of these drugs during the time of study participation:

1. Sensitive substrates for cytochrome P450 2C8 or 3A4 (e.g., repaglinide, midazolam, sildenafil)
2. Moderate or strong inhibitors or inducers of cytochrome P450 3A4 (e.g., carbamazepine, phenytoin, ciprofloxacin, grapefruit juice)
3. Substrates for p-glycoprotein transporter (e.g., ambrisentan, digoxin)
9. Have participated in any other interventional clinical study within 30 days prior to Study Day 1
10. Have a cognitive impairment that may preclude ability to comply with study procedures
11. Prior participation in a trial with omaveloxolone (RTA 408)
Minimum Eligible Age

16 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AbbVie

INDUSTRY

Sponsor Role collaborator

Friedreich's Ataxia Research Alliance

OTHER

Sponsor Role collaborator

Biogen

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UCLA

Los Angeles, California, United States

Site Status

University of Florida - Neurology

Gainesville, Florida, United States

Site Status

USF Ataxia Research Center

Tampa, Florida, United States

Site Status

Emory University Hospital - Neurology

Atlanta, Georgia, United States

Site Status

University of Iowa Stead Family Children's Hospital

Iowa City, Iowa, United States

Site Status

Ohio State University - Neurology

Columbus, Ohio, United States

Site Status

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Site Status

Murdoch Childrens Research Institute

Parkville, Victoria, Australia

Site Status

Medical University Innsbruck

Innsbruck, , Austria

Site Status

Neurological Institute Carlo Besta

Milan, , Italy

Site Status

University College of London

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil United States Australia Austria Italy United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Lynch DR, Chin MP, Delatycki MB, Subramony SH, Corti M, Hoyle JC, Boesch S, Nachbauer W, Mariotti C, Mathews KD, Giunti P, Wilmot G, Zesiewicz T, Perlman S, Goldsberry A, O'Grady M, Meyer CJ. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study). Ann Neurol. 2021 Feb;89(2):212-225. doi: 10.1002/ana.25934. Epub 2020 Nov 5.

Reference Type DERIVED
PMID: 33068037 (View on PubMed)

Lynch DR, Farmer J, Hauser L, Blair IA, Wang QQ, Mesaros C, Snyder N, Boesch S, Chin M, Delatycki MB, Giunti P, Goldsberry A, Hoyle C, McBride MG, Nachbauer W, O'Grady M, Perlman S, Subramony SH, Wilmot GR, Zesiewicz T, Meyer C. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia. Ann Clin Transl Neurol. 2018 Nov 10;6(1):15-26. doi: 10.1002/acn3.660. eCollection 2019 Jan.

Reference Type DERIVED
PMID: 30656180 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol: Main Protocol

View Document

Document Type: Study Protocol: United Kingdom Protocol

View Document

Document Type: Statistical Analysis Plan: Part 1

View Document

Document Type: Statistical Analysis Plan: Part 2

View Document

Document Type: Statistical Analysis Plan: Part 2 Addendum

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-517436-22

Identifier Type: OTHER

Identifier Source: secondary_id

RTA 408-C-1402

Identifier Type: -

Identifier Source: org_study_id